stockrow
Friday 6 November 2026
Export BIVI’s income statement to Excel — free account
BioVie Inc.
BIVI Healthcare Biotechnology
- EPS
- +63.0%
- Free cash flow
- +26.5%
Quarter to June 2026, against a year earlier
1.32
0.11
+9.09%
Follow BIVI
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.0 pt | ||||||
| EBT | (1) | (2) | (2) | (17) | (130) | (26) | (50) | (32) | (18) | (22) | +36.6% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (1) | (2) | (2) | (17) | (130) | (26) | (50) | (32) | (18) | (22) | +36.6% | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (186.07) | (317.74) | (96.23) | (685.00) | (1,482.00) | (106.00) | (155.00) | (73.00) | (12.12) | (3.05) | (36.7%) | ||||||
| Cash flow | (87.20) | (81.10) | (98.49) | (33.03) | (84.30) | (77.01) | (123.93) | (61.84) | (12.88) | (2.63) | (32.2%) | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (87.20) | (81.10) | (98.49) | (33.03) | (84.30) | (77.01) | (123.93) | (61.84) | (12.88) | (2.63) | (32.2%) | ||||||
| Book value | 161.83 | 14.52 | 83.89 | (436.08) | 40.73 | 14.89 | 47.23 | 34.31 | 12.87 | 1.42 | (40.9%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 7 | +115.8% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | (1) | (1) | (3) | (2) | (10) | (19) | (40) | (28) | (19) | (19) | +46.2% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | (1) | (1) | (3) | (2) | (10) | (19) | (40) | (28) | (19) | (19) | +46.2% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | (1) | (1) | 0 | (23) | 4 | 15 | 20 | 15 | 18 | 10 | n/m | |||||
| Net debt | 0 | 1 | 0 | 1 | (5) | (7) | (29) | (24) | (18) | (9) | n/m | ||||||
| Shareholders’ equity | 1 | 0 | 2 | (21) | 5 | 4 | 15 | 16 | 19 | 10 | +27.5% | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | (52.35) | (107.24) | (104.97) | (1,450.13) | (4,522.36) | (199.41) | (182.02) | (109.45) | (76.59) | (123.51) | (71.2) pt | |||||
| ROIC | 0.00 | 0.00 | (87.12) | 0.00 | (16,017.04) | 0.00 | 0.00 | 0.00 | (769.48) | (1,095.00) | (1,095.0) pt | ||||||
| ROE | (86.60) | (383.78) | (222.37) | 348.78 | 2,235.46 | (598.19) | (528.70) | (214.01) | (103.78) | (151.06) | (64.5) pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | 2 | 2 | 13 | 18 | 14 | 13 | 13 | +36.6% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
BioVie Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LPCN Lipocine Inc. | $12.6M | — (loss-making) | — (loss-making) | +1,898.32% (above 0%: growing) | n/m | +39.46% (above 0%: growing) | 100.00% | (37.93%) | Compare |
| TVRD Tvardi Therapeutics, Inc. | $11.5M | — (loss-making) | — (loss-making) | +20.33% (above 0%: growing) | n/m | −57.26% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| PBM Psyence Biomedical Ltd. | $11.2M | 0.1× | — | — | n/m | −707.20% (below 0%: shrinking) | — | 0.00% | Compare |
| PASG Passage Bio, Inc. | $11.1M | — (loss-making) | — | — | n/m | −59.81% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CLRB Cellectar Biosciences, Inc. | $10.9M | — (loss-making) | — | −73.23% (below 0%: shrinking) | n/m | −17.49% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LSTA Lisata Therapeutics, Inc. | $10.7M | — (loss-making) | — (loss-making) | −98.30% (below 0%: shrinking) | n/m | +33.04% (above 0%: growing) | 100.00% | 0.00% | Compare |
| BIVI BioVie Inc. | $10.3M | — (loss-making) | — | — | n/m | +26.50% (above 0%: growing) | 0.00% | 0.00% | |
| PTN Palatin Technologies, Inc. | $10.2M | 12.2× | 0.2× | −14.06% (below 0%: shrinking) | n/m | +34.21% (above 0%: growing) | 100.00% | (1,469.35%) | Compare |
| INTS Intensity Therapeutics Inc. | $10.1M | — (loss-making) | — | — | n/m | +4.72% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $11.0M | — | — | −14.06% | — | −6.38% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 28 September 2026
Ownership
Directors and executive officers, together
16.70%
Morgan Stanley
10.50%
Alta Partners LLC
8.10%
Jane Street Group, LLC
5.20%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement